Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study
Int. Journal of Clinical Pharmacology and Therapeutics · 2024
DOI: 10.5414/cp204492 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2024. Verfasst von Hansol Jeong und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Ustekinumab, Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Jeong, H., Kang, T., Lee, J., & Im, S. (2024). Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204492
Vancouver
Jeong H, Kang T, Lee J, Im S. Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study. Int. Journal of Clinical Pharmacology and Therapeutics. 2024. doi:10.5414/cp204492
BibTeX
@article{Jeong2024,
author = {Jeong, Hansol and Kang, Taeseung and Lee, Jiyoon and Im, Seongsik},
title = {Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2024},
doi = {10.5414/cp204492}
}
EUVIMED